Search Results

The Roche Scripts for COBAS AMPLICOR CT/NG Test are intended to provide software scripts to direct the automated Tecan Genesis RSP 150 Workstation to process swab samples or control material for analysis using either of the following 510(k)-cleared assay test systems:

• COBAS AMPLICOR™ CT/NG test for Chlamydia trachomatis
• COBAS AMPLICOR™ CT/NG test for Neisseria gonorrhoeae

The Roche Scripts for COBAS AMPLICOR CT/NG Test accessory consists of a compact disc (CDs) containing scripts to direct the automated Tecan Genesis RSP 150 workstation to process swab samples or control material for analysis.

The provided text describes a 510(k) summary for the COBAS AMPLICOR CT/NG test for Chlamydia trachomatis with Roche Scripts Accessory. However, it does not contain information about acceptance criteria or a study proving the device meets those criteria.

The document mainly focuses on:

• Device description and intended use of the COBAS AMPLICOR CT/NG test.
• Description of the Roche Scripts accessory (software) to automate sample processing.
• Comparison to a predicate device.
• The FDA's decision letter for 510(k) clearance, confirming substantial equivalence.
• Indications for Use for the Roche Scripts accessory.

There is no mention of:

1. A table of acceptance criteria and reported device performance.
2. Sample sizes used for test sets, data provenance.
3. Number of experts or their qualifications for ground truthing.
4. Adjudication methods.
5. Multi-reader multi-case (MRMC) comparative effectiveness studies.
6. Standalone algorithm performance.
7. Type of ground truth used.
8. Sample size for the training set.
9. How ground truth for the training set was established.

Therefore,Based on the provided text, I cannot describe the acceptance criteria or a study that proves the device meets the acceptance criteria, as this information is not present in the document. The document primarily focuses on the description and intended use of the device and its 510(k) clearance.

Ask a specific question about this device

The COBAS AMPLICOR CT/NG Test for Chlamydia trachomatis is a qualitative in vitro test for the detection of C. trachomatis plasmid DNA in urine from males and females, in endocervical swab specimens, and in male urethral swab specimens as evidence of symptomatic or asymptomatic infection with C. trachomatis. C. trachomatis DNA is detected by Polymerase Chain Reaction (PCR) amplification of target DNA and by hybridization capture of amplified target using the COBAS AMPLICOR Analyzer.

The COBAS AMPLICOR CT/NG Test for Chlamydia trachomatis is a multiplex in vitro diagnostic test performed on the COBAS AMPLICOR Analyzer. The COBAS AMPLICOR Analyzer automates the annolification, the nucleic acid hybridization, and the colorimetric detection procedures of the Test. The COBAS AMPLICOR CT/NG Test for Chlamydia trachomatis also has an Internal Control that identifies. specimens that contain substances inhibitory to PCR.

Here's a breakdown of the acceptance criteria and study details for the COBAS AMPLICOR™ CT/NG Test for Chlamydia trachomatis, based on the provided 510(k) summary:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state pre-defined "acceptance criteria" in terms of specific sensitivity and specificity thresholds that needed to be met. Instead, it presents the device's performance in comparison to existing gold standards (culture and DFA). The reported performance across various patient groups and specimen types allows implicit evaluation against generally accepted standards for diagnostic tests.

2. Sample Size and Data Provenance (Clinical Study)

• Test Set Sample Size:
  • Total Patients: 4277
  • Total Specimens (initially collected): 8523 (both swab and urine from 4201 patients; urine only from 76 patients)
  • Specimens included in primary analysis (with IC): 8397
  • Specimens included in analysis (without IC): 8478 (after excluding initial equivocal and repeatedly inhibitory results)
• Data Provenance: Retrospective, collected from six geographically diverse sites. Specific countries are not mentioned, but "US Highway 202 Somerville, New Jersey" for Roche suggests the study was likely conducted in the United States.

3. Number of Experts and Qualifications for Ground Truth

• The document does not specify the "number of experts" or their "qualifications" involved in establishing the ground truth.
• The ground truth method used was standard cell culture with immunofluorescent staining for C. trachomatis for positive samples.
• For swab specimens that were culture negative by the COBAS test, DFA (Direct Fluorescent Antibody) testing was performed for the presence of C. trachomatis. These are established laboratory methods.

4. Adjudication Method for the Test Set

• The document describes a hierarchical adjudication method for establishing the ground truth, rather than a traditional consensus by independent experts on the device's results.
• Primary Ground Truth: C. trachomatis cell culture (with cyclohexamide treated McCoy cells stained with fluorescein-labeled monoclonal antibody).
• Secondary Ground Truth (for culture-negative COBAS-positive swabs): DFA (Direct Fluorescent Antibody) for C. trachomatis.
• Tertiary Check (for information only): Alternate PCR testing (MOMP gene target) was performed on COBAS AMPLICOR positive, culture/DFA negative specimens, but these results were explicitly not used to calculate the clinical performance characteristics. This indicates a strict reliance on the established culture/DFA as the ground truth.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

• No MRMC comparative effectiveness study was done in the context of human readers directly interacting with or improving with AI assistance. This document describes the performance of a standalone in vitro diagnostic (PCR-based) test. The "readers" here are the laboratory technicians conducting and interpreting the instrument's output.

6. Standalone Performance

• Yes, a standalone study was done. The entire clinical performance section (Tables 3-7 and associated text) describes the performance of the COBAS AMPLICOR CT/NG Test as a diagnostic device without human-in-the-loop assistance in its interpretation beyond standard laboratory procedures (e.g., reading optical density and confirming results). It directly compares the device's output to the established gold standard.

7. Type of Ground Truth Used

• The primary ground truth used was a combination of expert-performed laboratory methods:
  • Cell Culture (with immunofluorescent staining) for C. trachomatis.
  • Direct Fluorescent Antibody (DFA) for C. trachomatis (used for culture-negative COBAS-positive samples).
• The MOMP PCR assay was an investigational check for false positives, but its results were not incorporated into the official performance metrics, highlighting adherence to established methods for ground truth.

8. Sample Size for the Training Set

• The document does not provide details on a separate "training set" as would be typical for machine learning algorithms. This device is an in vitro diagnostic (IVD) test, and its development typically involves internal validation and optimization against characterized samples, followed by clinical validation. The data presented is primarily for the clinical validation.

9. How the Ground Truth for the Training Set Was Established

• As there is no explicit "training set" discussed in the context of this 510(k) summary for an IVD, the method for establishing its ground truth is not detailed. However, for a device like this, the development process would have involved using characterized C. trachomatis strains and clinical samples with known infection status (determined by culture, etc.) to optimize the assay's primers, probes, and reaction conditions.

Ask a specific question about this device